Biomarin Pharmaceutical (BMRN) Liabilities and Shareholders Equity (2009 - 2026)

Biomarin Pharmaceutical has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $8.6 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 20.2% year-over-year to $8.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.3 billion (up 11.41% YoY) and the FY2025 annual result came in at $7.6 billion, up 8.66% from the prior year.
• Liabilities and Shareholders Equity advanced to $8.6 billion in Q1 2026, from $7.6 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $8.6 billion in Q1 2026 and troughed at $6.1 billion in Q1 2022.
• A 5-year average of $6.9 billion and a median of $6.9 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity climbed 1.38% — and 2026, when it grew 20.2%.
• Tracing BMRN's Liabilities and Shareholders Equity over 5 years: stood at $6.4 billion in 2022, then increased by 7.32% to $6.8 billion in 2023, then rose by 2.15% to $7.0 billion in 2024, then advanced by 8.66% to $7.6 billion in 2025, then climbed by 13.13% to $8.6 billion in 2026.
• Business Quant data shows BMRN's Liabilities and Shareholders Equity at $8.6 billion in Q1 2026, $7.6 billion in Q4 2025, and $7.6 billion in Q3 2025.